Cybin Inc.

NYSE American CYBN

Cybin Inc. Market Capitalization on January 14, 2025: USD 176.97 M

Cybin Inc. Market Capitalization is USD 176.97 M on January 14, 2025, a -38.78% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Cybin Inc. 52-week high Market Capitalization is USD 351.40 M on April 03, 2024, which is 98.56% above the current Market Capitalization.
Cybin Inc. 52-week low Market Capitalization is USD 151.94 M on September 17, 2024, which is -14.15% below the current Market Capitalization.
Cybin Inc. average Market Capitalization for the last 52 weeks is USD 233.25 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years